Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Thomas Ernst, Lioba Schönfeld, Jenny Rinke, Anna Hinze, Saskia N. Nagel, Vivien Schäfer, Thomas Schenk, Christian Fabisch, Tim H. Brümmendorf, Andreas Burchert, Philipp le Coutre, Stefan W. Krause, Susanne Saussele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 807–808.

https://doi.org/10.1182/blood-2022-165041

Published: 2022

Journal Articles

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Ulrich Jäger, Shirley D’Sa, Christian Schörgenhofer, Johann Bartko, Ulla Derhaschnig, Christian Sillaber, Petra Jilma-Stohlawetz, Michael Fillitz, Thomas Schenk, Gary Patou, Sandip Panicker, Graham C. Parry, James C. Gilbert, Bernd Jilma

Blood (2019) 133 (9): 893–901.

https://doi.org/10.1182/blood-2018-06-856930

Published: 2019

Includes: Supplemental data

Journal Articles

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Ulrich Jaeger, MD, Shirley D'Sa, MD FRCP, FRCPath, Christian Schoergenhofer, MD, Johann Bartko, MD, Christian Sillaber, MD, Petra Jilma-Stohlawetz, MD, Michael Fillitz, MD, Thomas Schenk, MD, Gary Patou, MD, Sandip Panicker, PhD, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD

Blood (2017) 130 (Supplement 1): 703.

https://doi.org/10.1182/blood.V130.Suppl_1.703.703

Published: 2017

Journal Articles

Hemophagocytic Lymphohistiocytosis in Adults (aHLH): Results from the German HLH Registry

Sebastian Birndt, Thomas Schenk, MD, Frank M. Brunkhorst, MD, Georg Maschmeyer, MD, Frank Rothmann, MD, Thomas Weber, MD, Markus Müller, MD, Jens P. Panse, MD, Roland Schroers, MD, Jan Braess, MD, Norbert Frickhofen, MD, Gritta Janka, MD PhD, Kai Lehmberg, MD, Andreas Hochhaus, MD, Thomas Ernst, MD, Paul La Rosée, MD

Blood (2016) 128 (22): 2523.

https://doi.org/10.1182/blood.V128.22.2523.2523

Published: 2016

Journal Articles

Adult Patients with Hemophagocytic Lymphohistiocytosis (HLH) in Germany: A Retrospective Multicenter Case Study of 29 Patients

Thomas Schenk, MD, Georg Maschmeyer, MD, Frank Rothmann, MD, Thomas Weber, MD, Maximilian Christopeit, MD, Olaf Penack, MD, PhD, Daniela Goy, MD, Jens Panse, MD, Gritta Janka, MD, PhD, Andreas Hochhaus, MD, Paul La Rosee, MD

Blood (2012) 120 (21): 3271.

https://doi.org/10.1182/blood.V120.21.3271.3271

Published: 2012

Journal Articles

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Martin C. Müller, MD, Umang Munjal, PhD, Philipp Erben, MD, Thomas Lion, MD, PhD, Gerlinde Mitterbauer-Hohendanner, MD, Hakim El Housni, MD, Nancy Boeckx, Renata Zadro, MD, PhD, Jiri Mayer, MD, PhD, Peter Rohon, MD, Jana Rulcova, PhD, Lykke Grubach, Kadri Raudsepp, MD, Veli Kairisto, MD, PhD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, MD, Sandrine Hayette, MD, Jean Gabert, MD, Jean-Michel Cayuela, MD, PhD, Christian Thiede, Lars Galonska, MD, Heike Pfeifer, MD, Carsten Hirt, MD, Philippe Schafhausen, MD, Nils von Neuhoff, PhD, Martin Roskos, MD, Christiane Pott, MD, Thoralf Lange, MD, Georg Hess, MD, Susanne Schnittger, PhD, Annika Dufour, MD, Steffen Koschmieder, MD, Frank Stegelmann, MD, Katerina Zoi, MD, PhD, Kostas Stamatopoulos, Hajnalka Andrikovics, MD, PhD, Tali Tohami, MD, PhD, Giovanni Martinelli, MD, Barbara Izzo, PhD, Enrico Gottardi, MD, Mindaugas Stoskus, Dag Andre Nymoen, MD, Tomasz Sacha, MD, Joana Diamond, MD, PhD, Rodica Talmaci, PhD, Andrey Misyurin, MD, Michael V. Dubina, MD, Tadej Pajic, MD, PhD, Josep F. Nomdedeu, MD, Dolors Colomer, MD, PhD, Gisela Barbany-Bustinza, MD, Hans Ehrencrona, MD, Elisabeth Oppliger Leibundgut, PhD, Jeroen Janssen, MD, Vincent H. J. van der elden, MD, Peter J.M. Valk, MD, PhD, Ugur Ozbek, MD, PhD, Lihui Wang, Gareth Gerrard, PhD, Helen E White, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Rüdiger Hehlmann, MD, Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Nicholas C. P. Cross, PhD

Blood (2010) 116 (21): 893.

https://doi.org/10.1182/blood.V116.21.893.893

Published: 2010

Journal Articles

Safety and Efficacy of the mTOR Inhibitor Everolimus as Early Interventional Replacement for Calcineurin Inhibitors In Graft-Versus-Host Disease (GvHD) Prophylaxis After Allogeneic Stem Cell Transplantation

Herbert G. Sayer, MD, Anne Klink, Thomas Schenk, MD, Anne Treschl, MD, Kristina Schilling, MD, Andreas Hochhaus, MD

Blood (2010) 116 (21): 2325.

https://doi.org/10.1182/blood.V116.21.2325.2325

Published: 2010

Journal Articles

MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure.

Mridul Agrawal, Philipp Erben, MD, Benjamin Hanfstein, Hannah Daikeler, MD, Juliana Popa, MD, Thomas Schenk, MD, Armin Leitner, MD, Richard C. Woodman, MD, Andreas Hochhaus, MD, Martin C Müller, MD

Blood (2009) 114 (22): 2615.

https://doi.org/10.1182/blood.V114.22.2615.2615

Published: 2009

Journal Articles

Harmonization of Molecular Monitoring of CML Therapy in Europe – Perspective of Widespread Competence in BCR-ABL Quantification.

Martin C Müller, MD, Nicholas C.P. Cross, Philipp Erben, MD, Thomas Schenk, MD, Thomas Ernst, MD, Rudiger Hehlmann, MD, Susan Branford, PhD, Giuseppe Saglio, Andreas Hochhaus, MD, for the EUTOS Molecular Monitoring Group

Blood (2009) 114 (22): 2616.

https://doi.org/10.1182/blood.V114.22.2616.2616

Published: 2009

Journal Articles

Downregulation of the Common Cytokine Receptor Subunit Beta c by Omacetaxine in CML: A Potential Molecular Mechanism to Overcome Cytokine-Mediated Resistance against BCR-ABL-Inhibitors.

Thomas Klag, MD, Nicolai Härtel, MD, Thomas Schenk, MD, Adam R Craig, MD, PhD, Andreas Hochhaus, MD, Paul La Rosee, MD

Blood (2009) 114 (22): 3256.

https://doi.org/10.1182/blood.V114.22.3256.3256

Published: 2009

Journal Articles

Placental Growth Factor: a Novel, Stromal-Derived Target in Human CML.

Sonja Loges, M.D., Ph.D, Thomas Schmidt, M.D., Christa Maes, Ph.D., Bart Jonckx, Maria Kleppe, Kim De Keersmaecker, Ph.D., Marc Tjwa, M.D., Ph.D., Thomas Schenk, M.D., Karolien Anne Beel, Christiane DeWolf-Peeters, M.D., Geert Carmeliet, M.D., Ph.D., Jan Cools, PhD, Richard E Clark, M.D., Peter Vandenberghe, MD, PhD, Tim H Brummendorf, M.D., Tessa Holyoake, M.D., Andreas Hochhaus, MD, Peter Carmeliet, M.D., Ph.D.

Blood (2009) 114 (22): 42.

https://doi.org/10.1182/blood.V114.22.42.42

Published: 2009

Journal Articles

Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.

Blood (2009) 114 (22): 862.

https://doi.org/10.1182/blood.V114.22.862.862

Published: 2009

Journal Articles

Association of Interphase Fluorescence in Situ Hybridization (IP-FISH) Response Criteria with Conventional Metaphase Cytogenetics in CML Patients On Therapy.

Thomas Schenk, MD, Martin C Müller, MD, Alice Fabarius, PhD, Philipp Erben, MD, Thomas Ernst, MD, Claudia Haferlach, MD, Andreas Hochhaus, MD

Blood (2009) 114 (22): 4707.

https://doi.org/10.1182/blood.V114.22.4707.4707

Published: 2009

Journal Articles

Weekend Drug Holiday of Dasatinib in CML Patients Not Tolerating Standard Dosing Regimens. Reducing Toxicity with Maintained Disease Control.

Paul La Rosee, MD, Armin Leitner, MD, Philippe Martiat, MD, Thomas Klag, MD, Samina Shazi, MD, Anne Treschl, MD, Martin C Müller, MD, Thomas Schenk, MD, Benjamin Hanfstein, Andreas Hochhaus, MD

Blood (2009) 114 (22): 1119.

https://doi.org/10.1182/blood.V114.22.1119.1119

Published: 2009

Journal Articles

Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.

Martin C. Mueller, MD, Philipp Erben, MD, Thomas Ernst, MD, Michelle Giehl, PhD, Thomas Schenk, MD, Jana Hoffmann, Stephanie Lauber, MD, Jens Kruth, MD, Benjamin Hanfstein, MD, Eric Bleickardt, MD, Claude Nicaise, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2007) 110 (11): 319.

https://doi.org/10.1182/blood.V110.11.319.319

Published: 2007

Journal Articles

Sensitive Detection of c-kit Point Mutations by D-HPLC in Peripheral Blood and Bone Marrow Samples from Patients with Systemic Mastocytosis.

Stephanie Lauber, MD, Martin C. Mueller, MD, Philipp Erben, MD, Thomas Schenk, MD, Jens Kruth, MD, Georgia Metzgeroth, MD, Thomas Ernst, MD, Peter Paschka, MD, Rudiger Hehlmann, MD, Andreas Reiter, MD, Andreas Hochhaus, MD

Blood (2006) 108 (11): 3624.

https://doi.org/10.1182/blood.V108.11.3624.3624

Published: 2006

Journal Articles

Diagnosis and Monitoring of Residual Disease by Quantitative RT-PCR in Eosinophilia-Associated Myeloproliferative Disorders with Rearrangements of PDGFRA and PDGFRB.

Philipp Erben, MD, Martin C. Mueller, MD, Georgia Metzgeroth, MD, Helena Popp, Christoph Walz, MD, Thomas Schenk, MD, Stephanie Lauber, MD, Jens Kruth, MD, Nicholas C.P. Cross, PhD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD, Andreas Reiter, MD

Blood (2006) 108 (11): 2690.

https://doi.org/10.1182/blood.V108.11.2690.2690

Published: 2006

Journal Articles

Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.

Martin C. Müller, MD, Philipp Erben, MD, Thomas Schenk, MD, Stephanie Lauber, MD, Jens Kruth, MD, Jana Hoffmann, Thomas Ernst, MD, Tanja Lahaye, MD, Georgia Metzgeroth, MD, Michael Acevedo, PhD, Claude Nicaise, MD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2006) 108 (11): 748.

https://doi.org/10.1182/blood.V108.11.748.748

Published: 2006

Journal Articles

Harmonization of BCR-ABL mRNA Quantification Using an Uniform Control Plasmid in 36 International Laboratories.

Martin C. Mueller, MD, Philipp Erben, MD, Giuseppe Saglio, MD, Enrico Gottardi, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Stephanie Lauber, MD, Michael Emig, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2005) 106 (11): 1991.

https://doi.org/10.1182/blood.V106.11.1991.1991

Published: 2005

Journal Articles

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

Paul La Rosée, MD, Susanne Holm-Eriksen, Thomas Ernst, MD, Heiko König, MD, Philipp Erben, MD, Martin Müller, MD, Thomas Schenk, MD, Michael Emig, MD, Anja Binckebanck, MD, Lydia Wunderle, MD, Leila Alland, MD, Peter Schuld, MD, Rüdiger Hehlmann, MD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD

Blood (2005) 106 (11): 497.

https://doi.org/10.1182/blood.V106.11.497.497

Published: 2005

NARROW

ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Hemophagocytic Lymphohistiocytosis in Adults (aHLH): Results from the German HLH Registry

Adult Patients with Hemophagocytic Lymphohistiocytosis (HLH) in Germany: A Retrospective Multicenter Case Study of 29 Patients

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Safety and Efficacy of the mTOR Inhibitor Everolimus as Early Interventional Replacement for Calcineurin Inhibitors In Graft-Versus-Host Disease (GvHD) Prophylaxis After Allogeneic Stem Cell Transplantation

MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure.

Harmonization of Molecular Monitoring of CML Therapy in Europe – Perspective of Widespread Competence in BCR-ABL Quantification.

Downregulation of the Common Cytokine Receptor Subunit Beta c by Omacetaxine in CML: A Potential Molecular Mechanism to Overcome Cytokine-Mediated Resistance against BCR-ABL-Inhibitors.

Placental Growth Factor: a Novel, Stromal-Derived Target in Human CML.

Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.

Association of Interphase Fluorescence in Situ Hybridization (IP-FISH) Response Criteria with Conventional Metaphase Cytogenetics in CML Patients On Therapy.

Weekend Drug Holiday of Dasatinib in CML Patients Not Tolerating Standard Dosing Regimens. Reducing Toxicity with Maintained Disease Control.

Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.

Sensitive Detection of c-kit Point Mutations by D-HPLC in Peripheral Blood and Bone Marrow Samples from Patients with Systemic Mastocytosis.

Diagnosis and Monitoring of Residual Disease by Quantitative RT-PCR in Eosinophilia-Associated Myeloproliferative Disorders with Rearrangements of PDGFRA and PDGFRB.

Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.

Harmonization of BCR-ABL mRNA Quantification Using an Uniform Control Plasmid in 36 International Laboratories.

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only